<DOC>
	<DOCNO>NCT02211742</DOCNO>
	<brief_summary>Dapagliflozin highly selective , reversible potent inhibitor sodium-glucose-linked Transporter 2 ( SGLT2 ) , successfully investigate use treatment option type 2 diabetes mellitus . The effect dapagliflozin increase glucosuria , show mean blood glucose concentration postprandial glucose excursion special significantly reduce type 2 diabetic patient . Due mechanism-of action seem likely also type 1 diabetic patient benefit dapagliflozin . The present study focus effect dapagliflozin fast glucose homeostasis postprandial glucose excursion male type 1diabetic patient . Participants subsequently receive 10 milligram dapagliflozin placebo 3 day ( equal 2 x 30mg per cross-over period ) double-blind , randomise , cross-over design . The effect measure via euglycemic hyperinsulinemic clamp study ( fast glucose homeostasis ) euglycemic oral glucose tolerance clamp test ( postprandial glucose excursion ) .</brief_summary>
	<brief_title>Dapagliflozin Type 1 Diabetes</brief_title>
	<detailed_description />
	<criteria>Type 1 diabetes mellitus ( duration disease least 5 year ) Cpeptide concentration &lt; 0.2Âµg/l male sex age 18 60 year Body Mass Index 20 25 kg/m2 measurable , clinically relevant ketonuria insufficient venous status forearm renal and/or hepatic insufficiency ( include microalbuminuria and/or albumin/creatininratio ) history cancer intake medication and/or substance capable influence insulin sensitivity within last 3 month prior study inclusion alcohol and/or drug abuse , nicotine consumption &gt; 5 cigarette / 24h brittlediabetes history severe hypoglycemia , define need foreign assistance independent actual blood glucose concentration measure history evidence clinically significant disorder , condition disease outline , opinion investigator may compromise ability participant give write informed consent , would pose risk subject safety , interfere study evaluation , procedures completion .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>dapagliflozin</keyword>
	<keyword>fast glucose</keyword>
	<keyword>postprandial glucose excursion</keyword>
	<keyword>euglycemic hyperinsulinemic clamp</keyword>
	<keyword>euglycemic oral glucose tolerance test</keyword>
</DOC>